Eyevensys
PulseSight Therapeutics is a clinical-stage biotech company that develops non-viral gene therapies for ophthalmology. The company focuses on treating severe eye diseases such as age-related macular degeneration (AMD), including late-stage dry AMD/Geographic atrophy and wet AMD. Its pipeline includes clinical trials for candidates like PST-611 and PST-809 to prevent blindness.
Biotech
Healthcare
Ophthalmology
Funding summary
- Total raised
- €44.5M
- Funding rounds
- 5
Investors in Eyevensys
Investors on record for Eyevensys. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Eyevensys?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors